- Home
- AG vs ACLX Comparison
AG vs ACLX Comparison
Compare AG & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.01
HOLD
Current Price
$68.70
Company Overview
Basic Information| Metric | AG | ACLX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AG | ACLX |
|---|---|---|
| Price | $15.01 | $68.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.25 | ★ $115.50 |
| AVG Volume (30 Days) | ★ 16.1M | 1.2M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $965,571,000.00 | $35,898,000.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | $18.81 | $302.49 |
| P/E Ratio | $108.04 | ★ N/A |
| Revenue Growth | ★ 83.84 | N/A |
| 52 Week Low | $5.09 | $47.86 |
| 52 Week High | $16.28 | $94.07 |
Technical Indicators
Market Signals| Indicator | AG | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 33.01 |
| Support Level | $14.84 | $66.00 |
| Resistance Level | $16.28 | $75.03 |
| Average True Range (ATR) | 0.83 | 5.23 |
| MACD | 0.36 | -1.69 |
| Stochastic Oscillator | 78.15 | 12.96 |
Price Performance
Historical Comparison AG
ACLX
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.